HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $25.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 255.11% from the company’s previous close.

QURE has been the subject of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target on shares of uniQure in a research report on Wednesday. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. The Goldman Sachs Group lowered their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday. Raymond James reiterated an “outperform” rating and set a $20.00 price target on shares of uniQure in a research report on Thursday, October 10th. Finally, Royal Bank of Canada lowered their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, uniQure currently has a consensus rating of “Hold” and a consensus target price of $17.00.

uniQure Price Performance

QURE traded up $0.98 during midday trading on Wednesday, hitting $7.04. The company had a trading volume of 1,082,880 shares, compared to its average volume of 1,410,732. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36. The company has a market capitalization of $342.85 million, a PE ratio of -1.19 and a beta of 0.90. uniQure has a twelve month low of $3.73 and a twelve month high of $11.35. The firm’s 50-day simple moving average is $5.68 and its 200-day simple moving average is $5.78.

Institutional Investors Weigh In On uniQure

Large investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new stake in shares of uniQure during the third quarter worth $53,000. Vanguard Personalized Indexing Management LLC increased its position in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares in the last quarter. Total Clarity Wealth Management Inc. bought a new stake in shares of uniQure during the second quarter worth $74,000. Finally, SG Americas Securities LLC bought a new stake in shares of uniQure during the second quarter worth $79,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.